Methylphenidate alleviates cognitive dysfunction from early Mn exposure: Role of catecholaminergic receptors
Stephane A Beaudin1, Shanna Howard1, Nicholas Santiago1
1Department of Microbiology and Environmental Toxicology, University of California, Santa Cruz, Santa Cruz, California, USA.
Abstract:
Environmental manganese (Mn) exposure is associated with impaired attention and psychomotor functioning, as well as impulsivity/hyperactivity in children and adolescents. We have shown previously that developmental Mn exposure can cause these same dysfunctions in a rat model. Methylphenidate (MPH) lessens impairments in attention, impulse control, and sensorimotor function in children, but it is unknown whether MPH ameliorates these dysfunctions when induced by developmental Mn exposure. Here, we sought to (1) determine whether oral MPH treatment ameliorates the lasting attention and sensorimotor impairments caused by developmental Mn exposure, and (2) elucidate the mechanism(s) of Mn neurotoxicity and MPH effectiveness. Rats were given 50 mg Mn/kg/d orally over PND 1-21 and assessed as adults in a series of attention, impulse control and sensorimotor tasks during oral MPH treatment (0, 0.5, 1.5, or 3.0 mg/kg/d). Subsequently, selective catecholaminergic receptor antagonists were administered to gain insight into the mechanism(s) of action of Mn and MPH. Developmental Mn exposure caused persistent attention and sensorimotor impairments. MPH treatment at 0.5 mg/kg/d completely ameliorated the Mn attentional dysfunction, whereas the sensorimotor deficits were ameliorated by the 3.0 mg/kg/d MPH dose. Notably, the MPH benefit on attention was only apparent after prolonged treatment, while MPH efficacy for the sensorimotor deficits emerged early in treatment. Selectively antagonizing D1, D2, or α2A receptors had no effect on the Mn-induced attentional dysfunction or MPH efficacy in this domain. However, antagonism of D2R attenuated the Mn sensorimotor deficits, whereas the efficacy of MPH to ameliorate those deficits was diminished by D1R antagonism. These findings demonstrate that MPH is effective in alleviating the lasting attention and sensorimotor dysfunction caused by developmental Mn exposure, and they clarify the mechanisms underlying developmental Mn neurotoxicity and MPH efficacy. Given that the cause of attention and psychomotor deficits in children is often unknown, these findings have implications for the treatment of environmentally-induced attentional and psychomotor dysfunction in children more broadly.
Insights
Environmental manganese exposure causes lasting attention and sensorimotor deficits in rats. Methylphenidate (MPH) effectively treats these attention and psychomotor impairments, offering potential therapeutic strategies for children.
Area of Science:
- Neuroscience
- Environmental Health
- Developmental Toxicology
Background:
- Environmental manganese (Mn) exposure is linked to attention and psychomotor deficits in children.
- Developmental Mn exposure induces similar neurodevelopmental dysfunctions in rodent models.
- The efficacy of methylphenidate (MPH) in ameliorating Mn-induced deficits remains uninvestigated.
Approach:
- Rats received oral Mn (50 mg/kg/d) during postnatal days 1-21.
- Adult rats were assessed for attention, impulse control, and sensorimotor function during MPH treatment (0-3.0 mg/kg/d).
- Catecholaminergic receptor antagonists were used to explore Mn neurotoxicity and MPH mechanisms.
Key Points:
- Developmental Mn exposure resulted in persistent attention and sensorimotor impairments in adult rats.
- Low-dose MPH (0.5 mg/kg/d) fully reversed attentional deficits; higher-dose MPH (3.0 mg/kg/d) ameliorated sensorimotor impairments.
- MPH's benefit for attention required prolonged treatment, while sensorimotor improvement was rapid.
Conclusions:
- MPH effectively alleviates lasting attention and sensorimotor dysfunction caused by developmental Mn exposure.
- D2 receptor antagonism attenuated Mn sensorimotor deficits; D1 receptor antagonism reduced MPH efficacy for these deficits.
- Findings support MPH as a potential treatment for environmentally-induced neurodevelopmental disorders in children.
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Drugs Affecting Neurotransmitter Synthesis
Drugs Affecting Neurotransmitter Release or Uptake


